Why Biomarker Testing Matters in Head and Neck Cancer
A recent article from OncLive highlights the growing importance of biomarker testing in head and neck cancers and how it is helping doctors make more personalised treatment decisions.
Dr Fangdi Sun from Stanford University explained that head and neck cancer is not one single disease, but a group of different cancers that can behave in different ways. Biomarker testing helps specialists better understand the specific type of cancer a person has and which treatments may work best for them.
The article discusses how testing can identify features such as HPV-related cancers, Epstein-Barr virus (EBV), and other genetic changes within tumours. These biomarkers can provide important information about diagnosis, likely outcomes, and whether targeted treatments or newer therapies may be suitable.
For some rare head and neck cancers, advanced genetic testing can also help doctors identify mutations or changes that may respond to specific medicines. In other cases, biomarker testing can help determine where a cancer may have started if it is first discovered in a lymph node.
The article highlights how modern cancer care is increasingly moving toward more personalised approaches, where treatment decisions are guided not only by where the cancer is located, but also by the biological characteristics of the tumour itself.
As research continues to advance, biomarker testing is expected to play an even greater role in improving diagnosis, treatment planning, and outcomes for people affected by head and neck cancer.
https://www.onclive.com/view/dr-sun-on-the-importance-of-biomarker-testing-in-head-and-neck-cancers
